In-silico Analysis of Adenosine Deaminase: From Gene Sequence Retrieval to Clinical Implications and Drug Targets
Article Sidebar
Main Article Content
Abstract
Background: Adenosine Deaminase (ADA) plays a critical role in purine metabolism and immune function. Its genetic and molecular characterization is essential for understanding its involvement in various physiological and pathological processes. The ADA gene has been implicated in immune system disorders and offers a potential target for therapeutic intervention.
Objective: This study aims to comprehensively analyze the ADA gene and its protein product, detailing the genetic structure, physiochemical properties, subcellular localization, expression patterns, clinical variations, functional domains, splice variants, and potential as a drug target, to enhance the understanding of its function in human health.
Methods: We utilized an array of in silico tools for gene sequence retrieval, including analysis of genomic databases for ADA's chromosomal location and gene structure. Physiochemical properties were determined using ProtParam, and subcellular localization was predicted with CELLO v.2.5. Gene expression levels across various tissues were ascertained using the Archive Ensemble TOOL. Clinical variations were categorized based on their potential pathogenicity, while splice variants and functional domains were predicted using domain-specific databases. Post-translational modifications were analyzed with prediction tools from the CBS server, and the STRING database facilitated protein interaction network analysis. Additionally, the DoG-Site Scorer predicted ADA's druggability profile.
Results: ADA was localized to chromosome 12 (20q13.12), comprising 45940 base pairs encoding 363 amino acids. The protein's molecular weight was calculated as 37948.09, with a total atom count of 5396. Predictive localization indicated periplasmic and cytoplasmic presence with reliability scores of 1.437*, 1.210*, and 1.058*. Expression profiling revealed high ADA levels in the duodenum, with a notable expression in the lymphatic node. Clinical variations identified included 21 insertions and 23 inversions, with two pathogenic instances. Splice variant analysis predicted nine sites, and drug-binding potential was identified with scores as high as 0.81.
Conclusion: Our study provides a detailed analysis of ADA, highlighting its genetic complexity and biological significance. The identification of clinically relevant gene variations and drug-binding pockets offers potential pathways for therapeutic intervention, emphasizing the importance of ADA in medical research and treatment strategies.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Marchetti M, Faggiano S, Mozzarelli A. Enzyme replacement therapy for genetic disorders associated with enzyme deficiency. Current Medicinal Chemistry. 2022;29(3):489-525.
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New England Journal of Medicine. 2009;360(5):447-58.
Giusti G. Adenosine deaminase. Methods of enzymatic analysis: Elsevier; 1974. p. 1092-9.
Cortés A, Gracia E, Moreno E, Mallol J, Lluís C, Canela EI, et al. Moonlighting adenosine deaminase: a target protein for drug development. Medicinal research reviews. 2015;35(1):85-125.
Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. Journal of leukocyte biology. 2010;88(2):279-90.
Vettenranta K, Raivio K. Activities of key enzymes of purine degradation and re-utilization in human trophoblastic cells. Placenta. 1988;9(1):27-37.
McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, et al. Analysis tool web services from the EMBL-EBI. Nucleic acids research. 2013;41(W1):W597-W600.
Garg VK, Avashthi H, Tiwari A, Jain PA, Ramkete PW, Kayastha AM, et al. MFPPI–multi FASTA ProtParam interface. Bioinformation. 2016;12(2):74.
Emanuelsson O, Brunak S, Von Heijne G, Nielsen H. Locating proteins in the cell using TargetP, SignalP and related tools. Nature protocols. 2007;2(4):953.
He X, Chang S, Zhang J, Zhao Q, Xiang H, Kusonmano K, et al. MethyCancer: the database of human DNA methylation and cancer. Nucleic acids research. 2007;36(suppl_1):D836-D41.
Julenius K. NetCGlyc 1.0: prediction of mammalian C-mannosylation sites. Glycobiology. 2007;17(8):868-76.
Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. 2004.
Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester‐Christensen MB, Schjoldager KTB, et al. Precision mapping of the human O‐GalNAc glycoproteome through SimpleCell technology. The EMBO journal. 2013;32(10):1478-88.
Blom N, Sicheritz‐Pontén T, Gupta R, Gammeltoft S, Brunak S. Prediction of post‐translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics. 2004;4(6):1633-49.
Duckert P, Brunak S, Blom N. Prediction of proprotein convertase cleavage sites. Protein Engineering Design and Selection. 2004;17(1):107-12.
Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic acids research. 2010;39(suppl_1):D561-D8.
Pan Y, Kang X. Limited dsRNA editing impedes leukemia stem cells. Trends in Cancer. 2024 Mar 7.
Rawat RS, Kumar S. Understanding the mode of inhibition and molecular interaction of taxifolin with human adenosine deaminase. Journal of Biomolecular Structure and Dynamics. 2023 Jan 22;41(2):377-85.
Cox JR, Jennings M, Lenahan C, Manion M, Courville S, Blazeck J. Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies. Immuno-Oncology and Technology. 2023 Sep 1;19:100394.
Arulselvan AJ, Manimuthu MS, Narayanaswamy R, Sankar M, Radhakrishnan N. Molecular Docking Analysis of Selected Urtica dioica Constituents As Human Carbonic Anhydrase II (hCA-II), Human 11 Beta-Hydroxysteroid Dehydrogenases Type 1 (h11beta-HSD1), and Human Dual Specificity Phosphatase (hCDC25B) Inhibitory Agents. Cureus. 2024 Feb 8;16(2).